Investmark Advisory Group LLC Acquires 12,852 Shares of Pfizer Inc. $PFE

Key Points

• Investmark Advisory Group LLC increased its holdings in Pfizer by 15.5%, acquiring an additional 12,852 shares, bringing its total ownership to about 95,608 shares valued at approximately $2.42 million.
• Pfizer's latest earnings report showed a profit of $0.78 per share, surpassing analysts' expectations, and the company's revenue rose 10.3% year-over-year to $14.65 billion.
• The company announced a quarterly dividend of $0.43, reflecting a strong yield of 7.0% with a payout ratio of 91.49%.

Investmark Advisory Group LLC raised its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 15.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 95,608 shares of the biopharmaceutical company's stock after purchasing an additional 12,852 shares during the period. Pfizer makes up about 1.2% of Investmark Advisory Group LLC's portfolio, making the stock its 24th largest holding. Investmark Advisory Group LLC's holdings in Pfizer were worth $2,423,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Bessemer Group Inc. grew its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK lifted its position in shares of Pfizer by 1.2% during the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock valued at $35,817,000 after acquiring an additional 17,032 shares during the period. CHURCHILL MANAGEMENT Corp acquired a new stake in shares of Pfizer during the 1st quarter worth $8,283,000. Alta Advisers Ltd increased its position in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after purchasing an additional 13,100 shares during the period. Finally, WCM Investment Management LLC raised its stake in Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after purchasing an additional 10,051 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Berenberg Bank reduced their price target on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Finally, Jefferies Financial Group raised their target price on Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Price Performance

Shares of NYSE:PFE opened at $24.51 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market cap of $139.32 billion, a price-to-earnings ratio of 13.03, a PEG ratio of 0.88 and a beta of 0.55. The firm has a 50 day simple moving average of $24.83 and a 200 day simple moving average of $24.36.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to analysts' expectations of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 earnings per share. The company's revenue was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.